ORLANDO, Fla.—The leader of Gilead Sciences' Kite Pharma is sure that anito-cel, the biotech’s next-generation multiple myeloma CAR-T challenger to Carvykti, is ready for prime time—and that the ...

Preliminary results from two trials of the gene therapy exagamglogene autotemcel (exa-cel) suggest the therapy offers an effective cure for beta-thalassemia and sickle cell disease in children younger ...

For decades, scientists have known that motor proteins like kinesin-2 ferry vital cargo along microtubule "highways" inside cells. But how these molecular vehicles identify and bind to the right cargo ...

Five plead guilty in first antifa terrorism case after Trump’s designation Woman says hospital discharged her in labor, leading to roadside birth ABC reporter's Jeffrey Epstein question to Trump ...

Please provide your email address to receive an email when new articles are posted on . Patients with sickle cell disease and beta-thalassemia reported substantial improvements in quality of life ...

Splinter Cell: Deathwatch brings Sam Fisher out of retirement for one final mission, but maybe it shouldn't have bothered. While it occasionally sparks into life in the final act (with Liev Schreiber ...

Erick Massoto is a Brazilian writer who's always loved film and TV and loves finding connections between them. That's why he supports double features, especially if they are of a modern film paired ...

CEL-SCI Corporation (NYSE:CVM) shares tumbled 38.19% in after-hours trading to $8.06 on Tuesday following the cancer immunotherapy company’s announcement of a $10 million public offering priced below ...

Obecabtagene autoleucel showed effective outcomes in both younger and older adults with relapsed/refractory B-cell acute lymphoblastic leukemia, with similar remission rates and chimeric antigen ...

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced it has reached an agreement with one of Saudi Arabia’s premier pharmaceutical and healthcare companies for a ...

(RTTNews) - CEL-SCI Corp. (CVM) announced that shareholders approved a 1-for-30 reverse stock split of its common stock during the company's annual shareholder meeting. The reverse split was ...